Get to know our clinical trials
Trial of epcoritamab in combination with rituximab and lenalidomide (R2) compared to R2 in subjects with relapsed or refractory follicular lymphoma
THE AIM OF THIS STUDY IS TO TEST WHETHER THE ADDITION OF A DRUG CALLED EPCORITAMAB TO TREATMENT WITH RITUXIMAB AND LENALIDOMIDE (R2) CAN IMPROVE RELAPSED (THAT HAS RECURRED) OR REFRACTORY (THAT HAD NOT IMPROVED) FOLLICULAR LYMPHOMA COMPARED TO TREATMENT WITH R2 ALONE.
Technical Summary
- PHASE 3 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO R2 IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (EPCORETM FL-1). IMMUNOTHERAPY
- Code EudraCT: 2021-000169-34
- Protocol number: M20-638
- Promoter: Abbvie Spain SLU
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.